IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of:)
DENNIS P. CURRAN et.al.)
Serial No. 10/663,605) NOVEL INTERMEDIATES IN THE
Filed: September 16, 2003	SYNTHESIS OF CAMPTOTHECIN AND RELATED COMPOUNDS AND
Art Unit: 1625	SYNTHESIS THEREOF
Examiner: Evelyn Mai Huang	
Atty Dock No.: 92-233 CIP D2)
·)))

Pittsburgh, Pennsylvania 15219 February 11, 2005

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence and any document referred to as enclosed herewith are being deposited with the United States Postal Service in an envelope as United States Express Mail addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

> Henry E. Bartony, Jr., Registration No 34, 772

> > February 11, 2005 Dated

INFORMATION DISCLOSURE STATEMENT

In compliance with Applicant's duty of disclosure under 37 C.F.R. § 1.56, Applicants submit the attached Forms PTO/SB/08a and PTO/SB/08b listing publications for consideration by the Examiner. Kindly, make these publications of record in the file of the application.

A copy of the non-patent documents listed in the attached Forms PTO/SB/08b is submitted herewith.

DENNIS P. CURRAN ET. AL.. Serial No.: 10/663,605

STATEMENT OF RELEVANCY

The relevance of the publications listed on attached Forms PTO/SB/08a and PTO/SB/08b is apparent from their disclosure.

The Examiner is respectively requested to initial a copy of the attached Forms PTO/SB/08a and PTO/SB/08b to show consideration of the publications, and to return the initialed form to the undersigned Attorney for Applicants.

Applicants note that although the cited references may be relevant to the examination of the above-referenced application, the filing of this Statement is not an admission that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in § 1.56(b).

Applicants believe that no fee of is required in connection with this Information Disclosure Statement. However, the United States Patent and Trademark Office is hereby authorized to charge any fee that may be required to Deposit Account No. 02-1065. A duplicate copy of this Information Disclosure Statement is transmitted herewith.

Respectfully submitted,

LIVINISA

Henry E. Bartony, Jr., Esq.

Reg. No. 34,772

Bartony & Hare, LLP

Law & Finance Building

429 Fourth Avenue, Suite 1801

Pittsburgh, Pennsylvania 15219

412-338-8632 (telephone)

412-338-6611 (fax)

Attorney for Applicants

EXPRESS MAIL LABEL No.: EL903357343US

Substitute for form 1449/PTO

Sheet

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Juder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/663,605	_	
Filing Date	SEPTEMBER 16, 2003		
First Named Inventor	DENNIS P. CURRAN	_	
Art Unit	1625	_	
Examiner Name	EVELYN MEI HUANG		
Attornov Docket Number	02 222 CID D2	_	

		••		DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	^{US-} 6,620,937	05-08-1995	CURRAN	
	A2	^{US-} 6,211,371	05-08-1995	CURRAN	
	A3	^{US-} 6,376,676	06-30-1993	CURRAN	
	A4	^{US-} 5,744,605	06-30-1993	CURRAN	
	A5	^{US-} 6,239,278	06-30-1993	CURRAN	
	A6	^{US-} 5,700,939	06-10-1993	FORTUNAK	
	A7	^{US-} 6,034,243	06-30-1993	CURRAN	
		US-			
_		US-			
		US-			

•		FORE	GN PATENT DOCU	MENTS		
	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		MM-DD-YYYY		Or Relevant Figures Appear	T ⁶	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

EXPRESS MAIL LABEL No.: EL903357343US

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	U.S. Fatent and Tradema		
Under the Paperwork Reduction Act of 1995, no persons are required to respond to	o a collection of informatio	n unless it contains a	valid OMB control number

Substitute for form 1449/PTO	Complete if Known		
	Application Number	10/663,605	
INFORMATION DISCLOSURE	Filing Date	SEPTEMBER 16, 2003	
STATEMENT BY APPLICANT	First Named Inventor	DENNIS P. CURRAN	
(Use as many sheets as necessary)	Art Unit	1625	
(030 as many sheets as necessary)	Examiner Name	EVELYN MEI HUANG	
Sheet 2 of 2	Attorney Docket Number	92-233 CIP D2	

Examiner Initials*	Cite No. ¹	N ON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C1	CURRAN, D.P. and LIU, H., "New 4+1 Radical Annulations A Formal Total Synthesis of (+/-)-Camptothecin," J. Am. Chem Soc., 114, 5863-5864 (1992). Published 7/1/92	
	C2	CURRAN, D.P., "The Camptothecins - A reborn Family of Antitumor Agents"," J. Chin. Chem. Soc., 40, 1-6 (1993). Published 2/1993	
	СЗ	CURRAN, D.P. et al., "Recent Applications of Radical Reactions in Natural Product Synthesis," Pure Appl. Chem., 65, 1153-1159 (1993). Published 6/93	
	C4	CURRAN; D.P. et al., "Cascade Radical Reactions of Isonitriles: A Second-Generation Synthesis of (20S)-Camptothecin, Topotecan, Irinotecan, and GI-147211C," Angew. Chem. Int. Ed, 34, 2683-2684 (1995). Published 1/5/96	-
	C5	CURRAN, D.P., Liu, H.; Josien, H; Ko, S.B., "Tandem Radical Reactions of Isonitriles with 2-pyrdonyl and other aryl radicals: Scope and Limitations, and a First Generation Sunthesis of (+/-)-Camptothecin," Tetrahedron, 52, 11385-11404 (1996). Published 8/96	
	C6	JOSIEN, H. and CURRAN, D.P., "Synthesis of (S)-mappicine and Mappicine Ketone Via Radical Cascade Reaction of Isonitirles," Tetrahedron, 53, 8881-8886 (1997). Published 6/30/97	
	C7	LIU, H. et al., "Selective N-Functionalization of 6-Substituted-2-Pyridones," Tetrahedron Letters, 36:49, 8917-8920 (1995).	
	C8	JOSIEN H. et.al." 7-Silylcamptothecins (Silatecans): A New Family of Camptothecin Antitumor Agents", Bioorganic & Medical Chemistry Letters, Oxford, GB, vol. 7, No. 24, Dec-16-1997, pages 3189-3194.	
	C9	SUGIMORI, M. et. al. Antitumor Agents. Synthesis and Antitunor activity of Ring A-, Ring B, and Ring C-Modified Derivatives of Camptothecin. Heterocycles. Vol. 38, No. 1, 1994	

Examiner	Date	
Signature	Considered	
ACMANDED 1 W 116 6		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citati on if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy or this form with next communication to applicant.

1 Applicant's unique citation designation number (optional).

2 Applicant's unique citation designation number (optional).

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.